Coastlands Capital Partners discloses 9.98% passive stake in Adial Pharmaceuticals
Coastlands Capital Partners disclosed a 9.98% passive stake in Adial Pharmaceuticals as of June 17 via an SEC Form 13G filing.

*this image is generated using AI for illustrative purposes only.
Coastlands Capital Partners disclosed a 9.98% passive stake in Adial Pharmaceuticals as of June 17. The investment was detailed in a Schedule 13G filing submitted to the U.S. Securities and Exchange Commission (SEC).
Filing Details
The filing indicates that Coastlands Capital Partners holds the stake in a passive capacity. The SEC Form 13G is used by institutional investors to report their ownership of shares exceeding 5% when they do not intend to exert control over the issuer.
Stakeholder Information
| Entity | Stake Percentage | Date |
|---|---|---|
| Coastlands Capital Partners | 9.98% | June 17 |
The disclosure provides transparency regarding significant ownership positions in Adial Pharmaceuticals.
What are Coastlands Capital Partners' strategic intentions with their near-10% stake in Adial Pharmaceuticals?
How might this significant ownership influence Adial Pharmaceuticals' future business decisions or strategic direction?
Could this stake signal potential upcoming collaborations or partnerships for Adial Pharmaceuticals?


























